Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.
The phenomenon of regression of adenocarcinoma of the prostate after the withdrawal of antiandrogens is well documented. However, to our knowledge we report the first case of durable complete remission of hormone refractory prostate cancer after cessation of diethylstilbestrol. The drug was discontinued because the patient had disease progression while on diethylstilbestrol and withdrawal resulted in durable remission. In more than 3 years of followup since discontinuing diethylstilbestrol there has been no evidence of clinical or biochemical recurrence.
Bissada
N K
NK
Department of Urology, Medical University of South Carolina, Charleston, USA.
Kaczmarek
A T
AT
D000230:Adenocarcinoma / Q000188:drug therapy; D004054:Diethylstilbestrol / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous; D011471:Prostatic Neoplasms / Q000188:drug therapy; D017211:Treatment Failure
D004054:Diethylstilbestrol